C60 Peptide Lipid Formulation for Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compositions fail to effectively accentuate the antioxidant and anti-inflammatory properties of fullerenes, which are desirable for biological applications.
Innovation Solution
A pharmaceutically acceptable formulation comprising C60, serrapeptase, and a tetrapeptide (such as ALA,GLU,ASP,GLY) or dipeptide (like L-carnosine or L-carnitine) suspended in lipids like olive or mussel oil, administered to inhibit or ameliorate inflammation and associated maladies in mammals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fullerenes are used in biological compositions, then antioxidant and anti-inflammatory properties are achieved, but the compositions fail to effectively accentuate these properties
Solution Approach 1:
The patent combines fullerene (C60) with specific peptides (tetrapeptide ALA,GLU,ASP,GLY or dipeptide L-carnosine/L-carnitine) and serrapeptase to create a composite formulation. This composite approach enhances the antioxidant and anti-inflammatory properties of fullerene by synergistic interactions between the components, resolving the contradiction between achieving these properties and effectively accentuating them.
Solution Approach 2:
The patent modifies the chemical and biological parameters of fullerene by combining it with specific peptide sequences and enzymes. This parameter change transforms the basic fullerene properties into an enhanced formulation with amplified antioxidant and anti-inflammatory activity, addressing the contradiction between having these properties and effectively demonstrating them.
2Device complexity
If C60 is administered alone, then simple composition is maintained, but anti-inflammatory effectiveness is insufficient
Solution Approach 1:
The patent merges C60 with specific peptides (tetrapeptide ALA,GLU,ASP,GLY or dipeptide L-carnosine/L-carnitine) and serrapeptase into a single formulation. This combining approach maintains relative simplicity while significantly enhancing anti-inflammatory effectiveness through the synergistic interaction of the merged components.
Solution Approach 2:
By creating a composite material system comprising C60, peptides, and serrapeptase, the patent achieves enhanced anti-inflammatory effectiveness without excessive complexity. The composite structure allows the components to work together synergistically, improving reliability while maintaining manageable formulation complexity.
3Reliability
If peptide combinations are added to C60 formulation, then anti-inflammatory properties are enhanced, but formulation complexity increases
Solution Approach 1:
The patent applies local quality by selecting specific peptide sequences (tetrapeptide ALA,GLU,ASP,GLY or dipeptide L-carnosine/L-carnitine) that have particular anti-inflammatory properties. This targeted approach enhances anti-inflammatory effectiveness while limiting formulation complexity to only the necessary components required for the therapeutic effect.
Solution Approach 2:
The patent changes the chemical composition parameters by incorporating specific peptide molecules with defined amino acid sequences. This parameter change enhances anti-inflammatory properties while maintaining formulation complexity at acceptable levels, as the added complexity is precisely targeted rather than comprehensive.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation demonstrates anti-inflammatory and antioxidant effects, improving immune function and reducing inflammation in joints and muscles, as evidenced by clinical trial results showing decreased pro-inflammatory cytokines and normal liver enzyme levels in canine subjects.
Implementation Method 1
fullerenes have triggered interest in the scientific community based upon fullerenes interesting properties. Fullerene has been found to comprise a number of desirable structural, physical, and chemical properties adaptable for biological uses including antioxidants
Implementation Method 2
a pharmaceutically acceptable formulation comprising a biologically compatible lipolized composition of C60, serrapeptase, and a tetrapeptide... inhibiting and/or ameliorating inflammation and/or a malady associated with inflammation
Data Source
AI summary
In some embodiments, a chemical composition may include C60, serrapeptase, or a tetrapeptide. The tetrapeptide may include ALA,GLU,ASP,GLY. In some embodiments, the chemical composition may include a dipeptide. The dipeptide may include carnosine or camatine. In some embodiments, the chemical composition may include at least one lipid. One or more components of the chemical composition may be suspended in and/or dissolved in the at least one lipid. At least one lipid may include olive oil or mussel oil. In some embodiments, a method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation comprising the chemical composition. The method may include inhibiting and/or ameliorating inflammation and/or a malady associated with inflammation. In some embodiments, the subject may include a human or a nonhuman mammal. Nonhuman mammals may include equines, canines, or felines.